Title : Effect of simvastatin on the resistance to EGFR tyrosine kinase inhibitors in a non-small cell lung cancer with the T790M mutation of EGFR.

Pub. Date : 2014 May 1

PMID : 24631288






3 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Simvastatin also strongly inhibited AKT activation, leading to suppression of beta-catenin activity and the expression of its targets, survivin and cyclin D1. Simvastatin AKT serine/threonine kinase 1 Homo sapiens
2 Both insulin treatment and AKT overexpression markedly increased p-beta-catenin and survivin levels, even in the presence of gefitinib and simvastatin. Simvastatin AKT serine/threonine kinase 1 Homo sapiens
3 Overall, these data indicate that simvastatin may overcome EGFR-TKI resistance in T790M mutant NSCLCs via an AKT/beta-catenin signaling-dependent down-regulation of survivin and apoptosis induction. Simvastatin AKT serine/threonine kinase 1 Homo sapiens